Genetic Technologies Current Ratio 2006-2021 | GENE

Genetic Technologies current ratio from 2006 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Genetic Technologies Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.02B $0.00B 15.82
2020-12-31 $0.01B $0.00B 14.57
2020-06-30 $0.01B $0.00B 10.88
2019-12-31 $0.00B $0.00B 2.95
2019-06-30 $0.00B $0.00B 2.14
2018-12-31 $0.00B $0.00B 3.99
2018-06-30 $0.01B $0.00B 4.13
2017-12-31 $0.01B $0.00B 7.02
2017-06-30 $0.01B $0.00B 7.94
2016-12-31 $0.01B $0.00B 9.47
2016-06-30 $0.01B $0.00B 9.10
2015-12-31 $0.01B $0.00B 13.78
2015-06-30 $0.02B $0.00B 11.28
2014-12-31 $0.00B $0.00B 1.53
2014-06-30 $0.00B $0.00B 1.89
2013-12-31 $0.01B $0.00B 5.50
2013-06-30 $0.00B $0.00B 1.08
2012-12-31 $0.01B $0.00B 3.82
2012-06-30 $0.01B $0.00B 5.16
2011-12-31 $0.01B $0.00B 9.22
2011-06-30 $0.01B $0.00B 3.09
2010-12-31 $0.01B $0.00B 4.34
2010-06-30 $0.00B $0.00B 1.82
2009-12-31 $0.01B $0.00B 2.46
2009-06-30 $0.01B $0.00B 2.67
2008-12-31 $0.01B $0.00B 4.29
2008-06-30 $0.01B $0.00B 5.22
2007-12-31 $0.01B $0.00B 6.16
2007-06-30 $0.01B $0.00B 4.21
2006-12-31 $0.01B $0.00B 3.16
2006-06-30 $0.01B $0.00B 4.75
2005-12-31 $0.01B $0.00B 5.66
2005-06-30 $0.02B $0.00B 4.02
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.044B $0.000B
Genetic Technologies was the first company in the world to recognize important new applications for `non-coding` DNA (DeoxyriboNucleic Acid). The Company has since been granted patents securing intellectual property rights for particular uses of non-coding DNA in genetic analysis and gene mapping across all genes in all multicellular species.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76